Atherton Lane Advisers’s Biogen BIIB Stock Holding History

Atherton Lane Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$302K	Sell	986 -200	-17%	-$57.5K	0.02%	185
2015 Q3	$346K	Hold	1,186	–	–	0.02%	162
2015 Q2	$479K	Buy	1,186 +6	+0.5%	+$2.41K	0.03%	149
2015 Q1	$498K	Sell	1,180 -85	-7%	-$33.5K	0.03%	170
2014 Q4	$429K	Buy	1,265 +132	+12%	+$42.7K	0.02%	189
2014 Q3	$375K	Sell	1,133 -27	-2%	-$8.9K	0.02%	197
2014 Q2	$366K	Sell	1,160 -8	-0.7%	-$2.41K	0.02%	206
2014 Q1	$357K	Buy	1,168 +22	+2%	+$6.98K	0.02%	114
2013 Q4	$320K	Hold	1,146	–	–	0.02%	120
2013 Q3	$276K	Buy	1,146 +51	+5%	+$11.4K	0.02%	115
2013 Q2	$236K	Buy	+1,095	New	+$234K	0.02%	126

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Atherton Lane Advisers's BIIB Position: Q4 2015 in Review

Atherton Lane Advisers reduced its Biogen (BIIB) stake by 17% in Q4 2015, selling an estimated $57.5K and leaving 986 shares worth $302K. The position accounts for 0.02% of the portfolio, ranked #185.

Atherton Lane Advisers first reported a position in BIIB in Q2 2013 and has held it in 11 quarters since. The position peaked at $498K in Q1 2015. 970 funds tracked by Wall St. Rank hold BIIB as of Q4 2015.

Atherton Lane Advisers held 986 shares of Biogen worth $302K as of Q4 2015.
Atherton Lane Advisers sold 200 Biogen shares in Q4 2015, an estimated $57.5K.
Biogen made up 0.02% of Atherton Lane Advisers's portfolio in Q4 2015, its #185 holding.
Atherton Lane Advisers first reported a position in Biogen in Q2 2013 and has held it in 11 quarters since.
Atherton Lane Advisers's Biogen position peaked at $498K in Q1 2015.
970 funds tracked by Wall St. Rank held Biogen as of Q4 2015.

Based on Atherton Lane Advisers's 13F filing for Q4 2015, filed 16 Feb 2016.